MD Anderson Cancer Center

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

The University of Texas MD Anderson Cancer Center announced that Albert Koong, MD, PhD, has been appointed chief scientific officer.

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.

The FDA has issued a ‘safe to proceed’ for an application for a novel CAR T-cell therapy in CD94-positive lymphomas.

The University of Texas MD Anderson Cancer Center released recent oncology research highlights.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Theresa Guise, MD, and Stephanie S. Watowich, PhD, of The University of Texas MD Anderson Cancer Center, have been elected fellows of the American Association for the Advancement of Science.

Peter WT Pisters, MD, received the Charles M. Balch, MD, Distinguished Service Award at the 2026 Society of Surgical Oncology Annual Meeting 

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center appointed new members to advance the institute’s immunotherapy work.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

MD Anderson data scientist Iakovos Toumazis, PhD, will further IDSO's goal to bring data science to inform decision-making for cancer control and public health.

Cancer vaccine, NOUS-209 was found to stimulate the immune system and target precancerous cells in Lynch Syndrome according to MD Anderson Cancer center.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

Researchers have developed the first genome-wide CRISPR screening tool for primary human natural killer cells.

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

The MD Anderson Cancer Center was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey.

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Studies have suggested that pre-surgical SRT may be comparable to standard post-surgical SRT in patients with resectable brain metastases.

MD Anderson researchers are enhancing CD19 CAR T-cell therapy outcomes in LBCL through precision medicine insights.

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.